Researchers have announced that tetrahydrocannabinol (THC), an active ingredient in marijuana, affects epigenetics, triggering structural and regulatory changes in the DNA of users’ sperm.
Genomics will change what patients expect from their provider, as well as change how physicians treat them. Before this happens, education on both sides is needed. This month we look at some of the big talking points.
A modified version of CRISPR has been used to reverse genetic obesity in two different mouse models without editing any genes. The technique uses the guidance system in CRISPR to target certain genetic sequences and amplifies existing gene activity to ramp up protein production.
The first findings from a comprehensive genomic analysis of the human brain have been unveiled, potentially uncovering a good deal about the inherited component of diseases such as schizophrenia and autism.
Personalised tumour-detecting cells from adult skin cells have been used to shrink brain tumours in mice by up to 5%, scientists have revealed. While the strategy has not yet been fully tested in people, it could in the future give doctors the ability to develop a custom treatment for certain cancer types.
Scientists from the University of Pennsylvania have created a test using gene-editing tools such as CRISPR to identify a gene variant responsible for severe hypertrophic cardiomyopathy (SHC). SHC is an often-familial disease which thickens heart walls and is linked to a variant in the TNNT2 gene.
An innovative gene therapy treatment for Parkinson’s seems to relieve symptoms by rewriting the brain, scientists have found. Following the success of the therapy study, the researchers are planning a larger trial to start at the end of 2019.
Time to pop the champagne – 100,000 genomes have been reached. Well done Genomics England!
A universal test which can detect traces of any cancer in a patient’s bloodstream in ten minutes has been developed by scientists from the University of Queensland. As it stands the test has a sensitivity of 90%, so is able to detect 90 in 100 cases of cancer.
APP, the gene responsible for making beta-amyloid in the brain, may be able to reshuffle its own DNA, scientists from Sanford Burnham Prebys Medical Discovery Institute in California have claimed. This development could explain why most drugs to treat Alzheimer’s, which are designed to remove beta-amyloid protein build-ups in the brain, have proven ineffective in clinical trials.
Machine learning can help healthcare workers predict whether patients may require emergency hospital admission, new study finds